Acute Leukemias

Table of Contents

1. Altmetric Badge
   Book Overview
2. Altmetric Badge
   Chapter 1 Multidrug Resistance and Its Circumvention in Acute Leukemia
3. Altmetric Badge
   Chapter 2 The Role of DNA Topoisomerase II in Multidrug Resistance in Human Leukemia
4. Altmetric Badge
   Chapter 3 Development of Sensitive Assays to Detect Antifolate Resistance in Leukemia Blasts
5. Altmetric Badge
   Chapter 4 Sequential Analysis of P-Glycoprotein Expression in Childhood Acute Lymphoblastic Leukemia
6. Altmetric Badge
   Chapter 5 Expression of the MDR1 Gene and Treatment Outcome in Acute Nonlymphocytic Leukemia
7. Altmetric Badge
   Chapter 6 Multidrug Resistance Proteins and their Functional Modulation in Human Leukemias as Analyzed by Flow Cytometry
8. Altmetric Badge
   Chapter 7 Reversal of Multidrug Resistance with a New Calcium/Calmodulin Antagonist
9. Altmetric Badge
   Chapter 8 Characterization of Human Leukemic HL-60 Sublines as a Model for Primary and Secondary Resistance Against Cytostatics
10. Altmetric Badge
    Chapter 9 Conserved Cytotoxic Activity of Aclacinomycin A in Multifactorial Multidrug Resistance
11. Altmetric Badge
    Chapter 10 Cytostatic Drug Resistance and Differentiation in Friend Erythroleukemia Cells
12. Altmetric Badge
    Chapter 11 On the Role of Aldehyde Dehydrogenase in a Cyclophosphamide-Resistant Variant of Brown Norway Rat Acute Myelocytic Leukemia
13. Altmetric Badge
    Chapter 12 SAENTA-fluoresceins: New Flow Cytometry Reagents for Assessing Transport of Nucleoside Drugs in Acute Leukemia
14. Altmetric Badge
    Chapter 13 Human Stem Cell Factor: Biological Effects and Receptor Expression on Myeloid Leukemia Cells
15. Altmetric Badge
    Chapter 14 Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Following Chemotherapy in Patients with High-Risk AML
16. Altmetric Badge
    Chapter 15 Use of Granulocyte-Macrophage Colony-Stimulating Factor Prior to Chemotherapy of Newly Diagnosed AML
17. Altmetric Badge
    Chapter 16 G-CSF after Intensive Induction Chemotherapy in Refractory Acute Leukemia and Bone Marrow Transplantation in Myeloid Leukemia
18. Altmetric Badge
    Chapter 17 Cytokinetic Resistance in Acute Leukemia: Recombinant Human Granulocyte Colony-Stimulating Factor, Granulocyte Macrophage Colony-Stimulating Factor, Interleukin-3 and Stem Cell Factor Effects In Vitro and Clinical Trials with Granulocyte Macrophage Colony-Stimulating Factor
19. Altmetric Badge
    Chapter 18 Simultaneous Administration of Granulocyte-Macrophage Colony-Stimulating Factor and Cytosine Arabinoside for the Treatment of High-Risk Myeloid Leukemia
20. Altmetric Badge
    Chapter 19 Modulation of Cytotoxicity and Differentiation-Inducing Potential of Cytosine Arabinoside in Myeloid Leukemia Cells by Hematopoietic Cytokines
21. Altmetric Badge
    Chapter 20 The Effect of Growth Factors on the Sensitivity of CFU-GM and CFU-Blasts to Cytosine Arabinoside
22. Altmetric Badge
    Chapter 21 Proliferation — Inducing Effects of Recombinant Human Interleukin-7 and Interleukin-3 in B-Lineage Acute Lymphoblastic Leukemia
23. Altmetric Badge
    Chapter 22 Interleukin-1 Production by Mononuclear Cells and Natural Killer Cell Activity in Children with Acute Lymphoblastic Leukemia
24. Altmetric Badge
    Chapter 23 Lymphokine Combination Vectors: A New Tool for Tumor Vaccination in Leukemias/Lymphomas
25. Altmetric Badge
    Chapter 24 Regulation of Erythropoietin Production in Patients with Myelodysplastic Syndromes
26. Altmetric Badge
    Chapter 25 Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia Patients by Polymerase Chain Reactions
27. Altmetric Badge
    Chapter 26 Detection of Minimal Residual Disease in B-Lineage Leukemia by Immunoglobulin Gene Fingerprinting
28. Altmetric Badge
    Chapter 27 Probing the Pathophysiology of Leukemic Response by Premature Chromosome Condensation
29. Altmetric Badge
    Chapter 28 Combination of In Situ Hybridization Cytogenetics and Immunologic Cell Identification in Diagnosing Minimal Residual Disease
30. Altmetric Badge
    Chapter 29 Detection of Residual Leukemic Cells in AML
31. Altmetric Badge
    Chapter 30 Detection of Residual Leukemic Cells in the Majority of AML Patients After the Administration of TAD9
32. Altmetric Badge
    Chapter 31 Flow Cytometric Characterization of Therapy-Resistant Leukemic Subpopulations in Relapse
33. Altmetric Badge
    Chapter 32 Chronic Myelogenous Leukemia in Blastic Phase: A Model of Heterogeneity and Resistance in Acute Leukemia
34. Altmetric Badge
    Chapter 33 Myelomonocyte Differentiation Antigens in the Diagnosis of Acute Nonlymphocytic Leukemia: the Relevance of CDw65 Antigen as a Screening Marker and the Prognostic Significance of CD15 Expression
35. Altmetric Badge
    Chapter 34 Surveillance of Acute Leukemia by Multiparameter Flow Cytometry
36. Altmetric Badge
    Chapter 35 Bone Marrow Blast Count at Day 28 as the Single Most Important Prognostic Factor in Childhood Acute Lymphoblastic Leukemia
37. Altmetric Badge
    Chapter 36 GM-CSF, CD14, and C-fms Genes in 12 Patients with 5q Abnormalities
38. Altmetric Badge
    Chapter 37 Characterization of the Predominant T-Cell Receptor Delta (TCRδ) Rearrangements in Non-T, Non-B ALL
39. Altmetric Badge
    Chapter 38 Diagnosis of Both c-ALL and Sarcoidosis in the Same Patient
40. Altmetric Badge
    Chapter 39 Pharmacologically Guided Leukemia Therapy
41. Altmetric Badge
    Chapter 40 Biochemical Basis for Combination Chemotherapy
42. Altmetric Badge
    Chapter 41 Interaction of Cytosine Arabinoside Accumulation and Cytosine Arabinoside Triphosphate Formation with Various Cytotoxic Drugs
43. Altmetric Badge
    Chapter 42 Dose-Dependent Cellular and Systemic Pharmacokinetics of Cytosine Arabinoside
44. Altmetric Badge
    Chapter 43 Enhanced Accumulation of dFdC Triphosphate in Tumor Cells with Short Retention of ARA-C Triphosphate
45. Altmetric Badge
    Chapter 44 Intracellular Pharmacokinetics of Cytosine Arabinoside in Leukemic and Normal Blood Cells
46. Altmetric Badge
    Chapter 45 Therapy of Relapsed Acute Myeloid Leukemia Using Targeted Plasma Concentrations of Cytosine Arabinoside and Etoposide
47. Altmetric Badge
    Chapter 46 Pharmacokinetics of High-Dose Etoposide Given in Diluted or Undiluted Form
48. Altmetric Badge
    Chapter 47 Clinical Implications of Idarubicin Pharmacology
49. Altmetric Badge
    Chapter 48 Mitoxantrone: Pharmacokinetic and Pharmacodynamic Studies in Patients with Leukemia
50. Altmetric Badge
    Chapter 49 Pharmacological Sanctuaries in the Treatment of Acute Leukemia in the Rat
51. Altmetric Badge
    Chapter 50 In Vitro Drug Resistance in Childhood Acute Lymphoblastic Leukemia in Relation to Age and Immunophenotype
52. Altmetric Badge
    Chapter 51 Drug Resistance in Children with Relapsed Acute Lymphoblastic Leukemia
53. Altmetric Badge
    Chapter 52 Sensitivity of Childhood Acute Lymphoblastic Leukemia Cells to Prednisolone and Dexamethasone Assessed by the MTT Assay
54. Altmetric Badge
    Chapter 53 Correlation of In Vitro Drug Resistance Assessed by the MTT Assay with Long Term Clinical Outcome in Childhood Acute Lymphoblastic Leukemia
55. Altmetric Badge
    Chapter 54 Prognostic Significance of Exposure to Intermediate-Dose Methotrexate in Children with Standard Risk ALL: The COALL 82/85 Experience
56. Altmetric Badge
    Chapter 55 Protein Binding of Teniposide In Vitro and in Children with Acute Lymphoblastic Leukemia
57. Altmetric Badge
    Chapter 56 Effect of Carboxymethylglucan-ara-C on Experimental Leukemia
58. Altmetric Badge
    Chapter 57 Plasma Pharmacology of Fludarabine and Cellular Bioavailability of Fludarabine Triphosphate
59. Altmetric Badge
    Chapter 58 Pharmacology of High-Dose 1,2,4-Triglycidylurazol in Preparative Regimens for Bone Marrow Transplantation: Preclinical Evaluation and First Clinical Results
60. Altmetric Badge
    Chapter 59 2,2′-Difluorodeoxycytidine: A New Antimetabolite with Inhibitory Activity Against Ribonucleotide Reduction dCMP Deaminase
61. Altmetric Badge
    Chapter 60 Screening of 19 Monoclonal Antibodies for their Potential as Ricin A-Chain Immunotoxins Against Myeloid Leukemia Cell Lines
62. Altmetric Badge
    Chapter 61 Patterns of Failure in Salvage Therapy for Acute Myelogenous Leukemia
63. Altmetric Badge
    Chapter 62 Cancer and Leukemia Group B Studies in Relapsed AML
64. Altmetric Badge
    Chapter 63 Clinical Trials in Adults with Relapsed and Refractory Acute Myelogenous Leukemia: The ECOG and the University of Rochester Experience
65. Altmetric Badge
    Chapter 64 Intermediate-Dose Cytarabine in the Treatment of Relapsed or Refractory Leukemias
66. Altmetric Badge
    Chapter 65 Mitoxantrone, Etoposide, and Intermediate-Dose Cytosine Arabinoside (MEC): An Effective Regimen for Refractory Acute Myeloid Leukemia
67. Altmetric Badge
    Chapter 66 Intermediate-Dose Arabinoside and Amsacrine: An Effective Regimen in Relapsed and Refractory Acute Leukemia
68. Altmetric Badge
    Chapter 67 High-Dose Versus Intermediate-Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age-Adjusted Randomized Comparison
69. Altmetric Badge
    Chapter 68 Treatment of Refractory and Relapsed Childhood Acute Myelogenous Leukemia with High-Dose Cytosine Arabinoside and Mitoxantrone (HAM): Results of the AML Relapse Study BFM-85
70. Altmetric Badge
    Chapter 69 Sequential Standard-Dose Cytosine Arabinoside/Mitoxantrone Therapy (SAM) in Adults with Acute Myeloid Leukemia
71. Altmetric Badge
    Chapter 70 Acute Myeloid Leukemia: An Update of Treatment Results with High-Dose Ara-C Consolidation Therapy
72. Altmetric Badge
    Chapter 71 Continuous Infusion of Mitoxantrone Combined with High-Dose Cytarabine (c-HAM) in Acute Myeloblastic Leukemia
73. Altmetric Badge
    Chapter 72 Treatment of Refractory and Relapsed Acute Leukemias with Cytosine Arabinoside and Mitoxantrone
74. Altmetric Badge
    Chapter 73 Mitoxantrone and VP-16,213 (MVP16) in AML Patients Refractory to Cytosine Arabinoside with Daunorubicin and High-Dose Cytosine Arabinoside with Amsidine: Preliminary Results
75. Altmetric Badge
    Chapter 74 Induction Therapy for Acute Myelogenous Leukemia with Idarubicin/Cytosine Arabinoside and Mitoxantrone/Etoposide in “Response-Adapted” Sequence
76. Altmetric Badge
    Chapter 75 Use of AMSA Combination Chemotherapy in Patients with Acute Myelogenous Leukemia Unsuitable for Anthracycline or Mitoxantrone Treatment
77. Altmetric Badge
    Chapter 76 Treatment of High-Risk Relapsing or Refractory AML with M-AMSA and ID-ARAC
78. Altmetric Badge
    Chapter 77 Aclacinomycin A/Etoposide Combination Therapy for Advanced Relapsed Acute Myeloid Leukemia: A Phase II Study of the Arbeitsgemeinschaft Internistische Onkologie
79. Altmetric Badge
    Chapter 78 Therapeutic Choices Influencing Duration of Complete Remission in Acute Myelogenous Leukemia
80. Altmetric Badge
    Chapter 79 Intensive Antileukemic Treatment for Advanced Primary Myelodysplastic Syndromes: Analysis of 30 Patients
81. Altmetric Badge
    Chapter 80 Treatment of Relapsed or Refractory Adult Acute Lymphocytic Leukemia
82. Altmetric Badge
    Chapter 81 Mitoxantrone and Continuous Infusion of Cytosine Arabinoside in the Treatment of Relapsed and Refractory Acute Leukemia
83. Altmetric Badge
    Chapter 82 Oral Idarubicin in Pretreated Pediatric Acute Leukemia
84. Altmetric Badge
    Chapter 83 Involvement of the CNS in Childhood AML: Experiences of the AML-BFM Studies -78, -83, and -87
85. Altmetric Badge
    Chapter 84 Modified REZ BFM 87 Protocol in Relapsed Childhood ALL: A Preliminary Report
86. Altmetric Badge
    Chapter 85 Platelet Transfusion in Patients with Bone Marrow Aplasia
87. Altmetric Badge
    Chapter 86 Renal Failure in Acute Leukemia: Incidence, Cause and Clinical Outcome
88. Altmetric Badge
    Chapter 87 Marrow Transplantation in Patients with Acute Myeloid Leukemia in First Remission, First Relapse or Second Remission
89. Altmetric Badge
    Chapter 88 Possible Effect of Autologous Blood Stem Cell Transplantation on Outcome of Acute Myeloid Leukemia in First Relapse
90. Altmetric Badge
    Chapter 89 Therapy of Acute-Phase Chronic Myelogenous Leukemia with Intensive Chemotherapy, Blood Cell Autotransplantation and Cyclosporine A
91. Altmetric Badge
    Chapter 90 Allogeneic Bone Marrow Transplantation in Patients with Acute Leukemia with More Advanced Disease
92. Altmetric Badge
    Chapter 91 Engraftment-Promoting Potential of High-Dose Cytostatic Agents in Allogeneic Bone Marrow Transplantation
93. Altmetric Badge
    Chapter 92 Impact of Total Body Irradiation and Marrow Transplantation in Early and Advanced Leukemia
94. Altmetric Badge
    Chapter 93 High-Dose ARA-C, Cyclophosphamide and Etoposide with Noncryopreserved Autologous Bone Marrow Transplantation in Acute Myeloid Leukemia in Remission: A Pilot Study
95. Altmetric Badge
    Chapter 94 Autologous Bone Marrow Transplantation in Patients with Acute Lymphoblastic Leukemia in Second or Subsequent Complete Remission
96. Altmetric Badge
    Chapter 95 Two Murine Leukemia Models for the Investigation of New Treatment Strategies in Bone Marrow Transplantation
97. Altmetric Badge
    Chapter 96 Immunomagnetic Removal of Malignant Cells from Human Bone Marrow Prior to Autologous Bone Marrow Transplantation
98. Altmetric Badge
    Chapter 97 High-Dose VP-16 (HD VP-16) and Fractionated Total Body Irradiation (F-TBI) Followed by Autologous Bone Marrow Transplantation (ABMT) in Children with Relapsed or High-Risk Acute Lymphoblastic Leukemia (ALL)
99. Altmetric Badge
    Chapter 98 Understanding the Mechanisms of Cure in Acute Myeloblastic Leukaemia: Towards a Modern Immunotherapy
100. Altmetric Badge
     Chapter 99 Interleukin 2 Treatment in the Management of Acute Leukemia Patients
101. Altmetric Badge
     Chapter 100 Assessment of Lymphokine-Activated Killer Activity Against Myeloid Leukemic Blasts and the Myeloid Cell Line K562 by Flow Cytometry
102. Altmetric Badge
     Chapter 101 Effect of Cyclosporine on the Frequency of LAK Precursor Cells In Vivo and In Vitro
103. Altmetric Badge
     Chapter 102 Adoptive Immunotherapy in Human and Canine Chimeras
104. Altmetric Badge
     Chapter 103 Interleukin-2 in the Treatment of Acute Myelocytic Leukemias: In Vitro Data and Presentation of a Clinical Concept
105. Altmetric Badge
     Chapter 104 State of the Art and Future Prospects of the Treatment of Acute Myeloid Leukemia
106. Altmetric Badge
     Chapter 105 Idarubicin Pharmacokinetics
107. Altmetric Badge
     Chapter 106 Toxicity Profile of Idarubicin: Experiences with Oral and Intravenous Idarubicin in the Treatment of Leukemia
108. Altmetric Badge
     Chapter 107 Prospective Study Comparing Idarubicin and Daunorubicin in Elderly Patients with Acute Myeloid Leukemia
109. Altmetric Badge
     Chapter 108 New Aspects in the Pharmacokinetics and Metabolism of Mitoxantrone
110. Altmetric Badge
     Chapter 109 Mitoxantrone in the Treatment of Acute Leukemias
111. Altmetric Badge
     Chapter 110 High-Dose Cytosine Arabinoside and Mitoxantrone (HAM) in the Treatment of Acute Leukemias: Results of Salvage and First Line Treatment
112. Altmetric Badge
     Chapter 111 Mitoxantrone, Cytosine Arabinoside and VP-16 (MAV) for De Novo Acute Myeloid Leukemia: A Pilot Study
113. Altmetric Badge
     Chapter 112 Role of Mitoxantrone, High-Dose Cytosine Arabinoside, and Recombinant Human GM-CSF in Aggressive Non-Hodgkin’s Lymphoma
114. Altmetric Badge
     Chapter 113 Treatment of Low-Malignant Non-Hodgkin’s Lymphoma by Cytoreductive Chemotherapy with Prednimustine/Mitoxantrone (PmM) Followed by Interferon-α2b Maintenance